Alaunos Therapeutics Inc
TCRT
View Detailed Chart
2.820USD
-0.160-5.37%
Close 03/30, 16:00（ET）Quotes delayed by 15 min
1.50MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
-5.37%
5 Days
-11.88%
1 Month
-15.06%
6 Months
+17.01%
Year to Date
-12.69%
1 Year
+93.15%
View Detailed Chart
TradingKey Stock Score of Alaunos Therapeutics Inc
Currency: USD Updated: 2026-03-27Key Insights
Alaunos Therapeutics Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 226 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Alaunos Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Alaunos Therapeutics Inc Highlights
StrengthsRisks
Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.
Growing
The company is in a growing phase, with the latest annual income totaling USD 10.00K.
Undervalued
The company’s latest PE is -1.32, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 107.75K shares, decreasing 54.73% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 30.06K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of -0.64.
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Alaunos Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Alaunos Therapeutics Inc Info
Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.
Ticker SymbolTCRT
CompanyAlaunos Therapeutics Inc
CEOWeis (Holger)
Websitehttps://alaunos.com/
Related Instruments
+0.96%
+1.56%
+0.85%
+2.90%
-1.28%
+1.78%
+1.47%
+0.07%
+0.00%
+2.70%
-2.08%
-0.13%
+0.72%
+2.03%
+2.33%
0.00%
+1.57%
-0.13%
+2.63%
+2.01%Popular Symbols
246.630
-2.170 (-0.87%)
165.170
-2.350 (-1.40%)
67831.210
+1209.810 (+1.82%)
251.670
-23.670 (-8.60%)
2067.550
+46.850 (+2.32%)
355.280
-6.550 (-1.81%)
4565.950
+55.170 (+1.22%)
101.211
-3.051 (-2.93%)
1.148
+0.001 (+0.09%)
159.612
-0.047 (-0.03%)
